You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC / CE

Innovations in Schizophrenia

  • Authors: Leslie Citrome, MD, MPH; Christoph U. Correll, MD; Jonathan Meyer, MD
  • CME / ABIM MOC / CE Released: 7/7/2022
  • Valid for credit through: 7/7/2023
Start Activity

  • Credits Available

    Physicians - maximum of 2.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 2.50 ABIM MOC points

    Nurses - 2.50 ANCC Contact Hour(s) (1 contact hours are in the area of pharmacology)

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for psychiatrists, primary care physicians (PCPs), nurse practitioners (NPs), and physician assistants (PAs).

The goal of this activity is that learners will be better able to screen, diagnose, treat, and manage patients with schizophrenia.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Best practices in forming effective and engaging relationships with patients with schizophrenia   
    • Implications of 2 common comorbidities, depression and anxiety, with respect to clinical management and treatment decisions for patients with schizophrenia  
    • Recent clinical trial data on emerging and novel treatments for schizophrenia  
    • Prevalence and risk factors for tardive dyskinesia (TD) among patients on antipsychotic medication  
    • The clinical management of patients with treatment-resistant schizophrenia  
  • Have greater competence related to
    • Implementing an evidence-based approach to controlling TD symptoms in patients on antipsychotic medications  
    • Assessing patients for treatment-resistant schizophrenia  


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Medscape policies. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.


Faculty

  • Leslie Citrome, MD, MPH

    Clinical Professor 
    Psychiatry and Behavioral Sciences 
    New York Medical College 
    Valhalla, New York 

    Disclosures

    Leslie Citrome, MD, MPH, has the following relevant financial relationships:  
    Consultant or advisor for: AbbVie/Allergan; Acadia; Adamas; Alkermes; Angelini; Astellas; Avanir; Axsome; BioXcel; Boehringer Ingelheim; Cadent Therapeutics; Eisai; Enteris BioPharma; HLS Therapeutics; Impel; Intra-Cellular Therapies; Janssen; Karuna; Lundbeck; Lyndra; Medavante-ProPhase; Merck; Neurocrine; Novartis; Noven; Otsuka; Ovid; Relmada; Reviva; Sage; Sunovion; Supernus; Teva 
    Speaker or member of speakers bureau for: AbbVie/Allergan; Acadia; Alkermes; Angelini; Eisai; Intra-Cellular Therapies; Janssen; Lundbeck; Neurocrine; Noven; Otsuka; Sage; Sunovion; Takeda; Teva 
    Stock options from: Reviva 
    Owns stock (publicly traded) in: Bristol Myers Squibb; Eli Lilly and Company; Johnson & Johnson; Merck Sharp & Dohme Corp; Pfizer

  • Christoph U. Correll, MD

    Professor of Psychiatry and Molecular Medicine 
    The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell 
    Hempstead, New York 
    Investigator 
    Center for Psychiatric Neuroscience 
    Feinstein Institute for Medical Research 
    Manhasset, New York 

    Disclosures

    Christoph U. Correll, MD, has the following relevant financial relationships:  
    Consultant or advisor for: AbbVie; Acadia; Alkermes; Allergan; Angelini; Aristo; Boehringer Ingelheim; Cardio Diagnostics; Cerevel; CNX Therapeutics; Compass Pathways; Damitsa; Gedeon Richter; Hikma; Holmusk; Intra-Cellular Therapies; Janssen/Johnson & Johnson; Karuna; LB Pharma; Lundbeck; MedAvante-ProPhase; MedInCell; Merck; Mindpax; Mitsubishi Tanabe Pharma; Mylan, Neurocrine; Noven; Otsuka; Pharmabrain; Recordati; Relmada; Reviva; Rovi; Seqirus; Servier; SK Life Science; Sunovion; Sun Pharma; Supernus; Takeda; Teva; Viatris 
    Speaker or member of speakers bureau for: AbbVie; Angelini; Aristo; Damitsa; Gedeon Richter; Hikma; Intra-Cellular Therapies; Janssen/Johnson & Johnson; Lundbeck; Mitsubishi Tanabe Pharma; Mylan; Otsuka; Recordati; Seqirus; Sunovion; Takeda; Viatris 
    Research funding from: Janssen; Takeda 
    Contracted researcher for: Janssen 
    Stock options from: Cardio Diagnostics; Mindpax; LB Pharma 

  • Jonathan Meyer, MD

    Clinical Professor 
    Department of Psychiatry 
    University of California San Diego 
    La Jolla, California 

    Disclosures

    Jonathan Meyer, MD, has the following relevant financial relationships:  
    Consultant or advisor for: Acadia Pharmaceuticals; Alkermes; Intra-Cellular Therapies; Karuna; Neurocrine; Otsuka America, Inc.; Sunovion; Teva 
    Speaker or member of speakers bureau for: Alkermes; Intra-Cellular Therapies; Noven; Sunovion; Teva

Editor

  • Lisette Arnaud-Hevi, , PhD

    Medical Education Director, Medscape, LLC

    Disclosures

    Lisette Arnaud-Hevi, PhD, has no relevant financial relationships.

Compliance Reviewer/Nurse Planner

  • Stephanie Corder, ND, RN, CHCP

    Associate Director, Accreditation and Compliance, Medscape, LLC 

    Disclosures

    Stephanie Corder, ND, RN, CHCP, has no relevant financial relationships. 

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 2.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

    For Nurses

  • Awarded 2.50 contact hour(s) of continuing nursing education for RNs and APNs; 1.0 contact hours are in the area of pharmacology.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC / CE

Innovations in Schizophrenia

Authors: Leslie Citrome, MD, MPH; Christoph U. Correll, MD; Jonathan Meyer, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 7/7/2022

Valid for credit through: 7/7/2023

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

The Power of Early Intervention and the Therapeutic Alliance for Patients With Schizophrenia ​

Learn with Dr Correll about the best practices in forming effective and engaging relationships with patients with schizophrenia.
Christoph U. Correll, MD

Key Questions on Common Comorbidities in Schizophrenia: A Focus on Depression and Anxiety

Hear about 2 of the most common comorbidities of schizophrenia and how to manage them.
Jonathan Meyer, MD

Tardive Dyskinesia: Causes, Consequences, and What to Do About It

Dr Citrome reviews the risk factors for tardive dyskinesia and how to control the symptoms.
Leslie Citrome, MD, MPH

Novel Approaches in Schizophrenia Treatment

Dr Correll reviews the latest developments on pharmacotherapies for schizophrenia.
Christoph U. Correll, MD

Addressing Treatment-Resistant Schizophrenia: Best Practices in Assessment and Management

Hear about how to identify a patient resistant to treatment and how to improve their chances of response.
Jonathan Meyer, MD
 

Educational Impact Challenge

The goal of this activity is that learners will be better able to screen, diagnose, treat, and manage patients with schizophrenia.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.